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Abstract
Conditional power calculations are frequently used to guide the decision whether or not
to stop a trial for futility or to modify planned sample size. These ignore the information in
short-term endpoints and baseline covariates, and thereby do not make fully efficient use of
the information in the data. We therefore propose an interim decision procedure based on the
conditional power approach which exploits the information contained in baseline covariates and
short-term outcomes. We will realise this by considering the estimation of the treatment effect
at the interim analysis as a missing data problem. This problem is addressed by employing
specific prediction models for the long-term endpoint which enable the incorporation of baseline
covariates and multiple short-term endpoints. We show that the proposed procedure leads to
an efficiency gain and a reduced sample size, without compromising the Type I error rate
of the procedure, even when the adopted prediction models are misspecified. In particular,
implementing our proposal in the conditional power approach allows earlier decisions relative
to standard approaches, whilst controlling the probability of an incorrect decision. This time
gain results in a lower expected number of recruited patients in case of stopping for futility,
such that fewer patients receive the futile regimen. We explain how these methods can be
used in adaptive designs with unblinded sample size reassessment based on the inverse normal
p-value combination method to control type I error. We support the proposal by Monte Carlo
simulations based on data from a real clinical trial.
Keywords: Interim analysis, Conditional power, Sample size re-assessment, Combination test,
Adaptive design
1 Introduction
Statistical rules to guide the decision of whether or not to stop a clinical trial early for futility
and to adapt the sample size are often based on the conditional power (e.g. Halperin et al. ,1982;
Lachin, 2005). This monitoring approach quantifies the probability of rejecting the null hypothesis
at the end of the study based on a chosen statistical test, given the primary endpoint data observed
thus far and an assumption about the future primary endpoint data (e.g. the effect size used when
powering the study). While this methodology is easy to implement and typically well understood
by the clinical team, it ignores information in short-term endpoints and baseline variables that
can improve the precision of treatment effect estimates. Such increased precision implies a higher
probability of stopping early for futility in the absence of a treatment effect, a reduction in average
sample size after sample size reassessment and a gain in time.
In view of the above, recent research has focused on incorporating predictive baseline covariates
(Qian et al. , 2018) and short-term measurements in interim analyses (e.g. Stallard, 2010; Hampson
and Jennison, 2013; Niewczas et al. , 2016). This brings several challenges. First, the additional
information accrued between the interim analysis and the final analysis may involve observations
of subjects who already contributed information to the interim analysis. This makes it more
challenging to maintain whether the independent increments property of the Brownian motion
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structure, used to justify the conditional power approach (Lachin, 2005). Second, the incorporation
of baseline covariates and short-term endpoints requires the postulation of statistical models. This
raises concerns that their misspecification may result in bias (Austin et al. , 2010; Assmann et al. ,
2000; Pocock et al. , 2002).
In this paper, we will overcome the abovementioned two concerns. For this, the precision of the
treatment effect estimator at the interim analysis will be optimized by incorporating short-term
endpoints as well as baseline covariates. We will realise this by considering the estimation of the
treatment effect at the time of the interim analysis as a missing data problem. This problem
can be addressed by making use of specific prediction models for the long-term endpoint which,
besides multiple short-term endpoints, can also incorporate baseline covariate information. This
methodology surprisingly has the appealing feature that it delivers a consistent treatment effect
estimator. Of all estimators that have this property, the considered one is most efficient (provided
that all models are correct). The proposed estimator is closely related to one given in the appendix
of Qian et al. (2016). In contrast to Qian et al. (2016), we justify the proposed procedure to
imbed the interim test statistic based on this proposed interim estimator in the conditional power
approach by relating to the general work of Scharfstein et al. (1997) on an information based-
design and monitoring procedure. This extension of the conditional power approach allows earlier
stopping for true futility whilst controlling the probability of incorrectly stopping. This generally
leads to a reduction in the number of recruited patients in the case of stopping for futility, such
that fewer patients receive the futile regimen.
Moreover, to further allow for modifying the design of the remaining study if the trial is not
stopped early for futility, we next extend the method to adaptive designs with unblinded sample
size reassessment based on conditional power arguments (Bauer and König, 2006). Since sample
size adaptations can inflate the type I error (Bretz et al. , 2009), we use the adaptive combination
test proposed by Bauer (1989) and Bauer and Köhne (1994) based on the inverse normal method
as the combination function (Lehmacher and Wassmer, 1999). We also justify the independence
of the stage-wise test statistics used in the combination test by relating to the general work in
Scharfstein et al. (1997). We support the proposal with simulation studies based on data from a
real clinical trial.
1.1 Motivating Example
The motivating phase 3 clinical trial was designed to evaluate the efficacy of a new experimental
treatment for multidrug-resistant tuberculosis on top of the standard of care regimen (referred
to as background regimen BR) as compared to placebo plus BR with regard to the proportion
of subjects with a favorable treatment outcome (ClinicalTrials.gov, NCT00449644 [7]) defined
as confirmed culture conversion 60 weeks after randomization. Besides the clinical endpoint of
interest, (predictive) baseline covariates as well as confirmed culture conversion (cure) 16 weeks
after randomization were planned to be measured. The available prior phase 2b data suggested
that the early measurements are reasonably predictive of the the long-term measurements, in the
sense that for the majority of subjects achieving the primary endpoint (culture conversion at week
60), culture conversion is expected to have occurred by week 16.
An interim analysis was planned to be performed prior to enrollment completion to evaluate
whether the data collected up to that point contain any evidence for superiority and if not, the
trial would be stopped for futility. Since many enrolled patients may have no information on the
primary endpoint available at the time of the interim analysis, restricting the interim analysis to
those patients with long-term information available may result in lack of information to support
futility decisions. To have a reasonable chance of detecting true futility early, we will include
information on baseline covariates and short-term endpoints into interim analyses of the long-term
endpoint, and thereby make fully efficient use of the information in the data. Guided by this
motivating example, the paper will focus on binary endpoints. However, the proposed approach is
applicable to other endpoints (e.g. continuous and survival endpoints).
2
2 Setting and Estimation
2.1 Trial Design
Consider a study design which intends to collect i.i.d. data {(Yi, Xi, Zi, Ai), i = 1, . . . , n}, with Yi
the binary primary endpoint, Xi a correlated short-term endpoint and Zi a vector of prognostic
baseline covariates (e.g. age, gender, . . . ) for patient i who is randomly assigned to either ex-
perimental treatment (Ai = 1) or control (Ai = 0). For pedagogic purposes, we consider a single
short-term endpoint X, but all results extend directly to the general case with multiple short-term
endpoints. Let nj (j ∈ {0, 1}) correspond to the pre-planned number of patients in each treatment
arm and n = n1 + n0 the planned sample size. Define Pj (j ∈ {0, 1}) as the probability of a
successful outcome at the end of a trial in the experimental (j = 1) and control (j = 0) arm.
The primary hypothesis of interest, H0 : P1 = P0, will be tested against the one-sided alternative,
HA : P1 > P0 at level α with power 1 − β. To evaluate this hypothesis, the test statistic for the
difference in marginal sample proportions of the two arms is compared to z1−α:
Z =
Pˆ1 − Pˆ0√
Pˆ1(1−Pˆ1)
n1
+ Pˆ0(1−Pˆ0)n0
,
where Pˆ1 =
∑n
i=1 AiYi∑n
i=1 Ai
and Pˆ0 =
∑n
i=1(1−Ai)Yi∑n
i=1(1−Ai) denote the estimated probability of a successful
outcome at the end of the trial in respectively the experimental and control arm respectively.
2.2 Effect Estimates at the Interim Analysis
Consider an interim analysis of the primary endpoint Y and assume that patients are continuously
recruited during the course of the trial. Since not all patients have full data observed at the interim
analysis, we use CYi to denote whether Yi is already observed (CYi = 1) or not (CYi = 0), CXi
to denote whether Xi is already observed (CXi = 1) or not (CXi = 0) and CZi to denote the
missingness status of Zi: CZi = 1 if and only if Zi is observed (i.e. if and only if patient i has
been enrolled in the study at the time of the interim analysis). The estimation of the effect at an
interim analysis can then be seen as a missing data problem, where we can distinguish 4 cohorts
of patients: a first cohort of patients for whom all data are available ((CZi , CXi , CYi )=(1, 1, 1)),
a second cohort of patients who passed the timepoint at which X is evaluated but not yet Y and
thus for whom only Z and X are observed ((CZi , CXi , CYi )=(1, 1, 0)), a third cohort of patients
for whom only Z is observed ((CZi , CXi , CYi )=(1, 0, 0)) and a fourth cohort of patients who have
not yet been recruited ((CZi , CXi , CYi )=(0, 0, 0)). Although the end-of-study outcome under the
experimental treatment is only seen for the treated patients in cohort 1, under the assumption that
recruitment occurs randomly (i.e. independent censoring holds, in the sense that (CZi , CXi , CYi )
is independent of Zi, Ai and the potential outcomes of Yi and Xi), the missing outcomes for the
other recruited patients on treatment can be unbiasedly predicted in large samples (Tsiatis, 2006).
Similar to the closely related estimator described in the appendix of Qian et al. (2016), this can
de done as follows:
1. regress Y on X and Z among the patients in cohort 1 of the treatment arm (CY = 1 and
A = 1) using a canonical generalized linear working model for the conditional mean of Y :
E(Y |A = 1, X,Z) = h1(X,Z,η0), where h1(X,Z,η) is a known function, evaluated at a
parameter η with unknown population value η0; for example h1(X,Z,η) = logit−1(η1 +
η2X + η3Z),
2. use this regression model to predict the outcome under the experimental treatment for the
treated patients in cohort 2 (CX = 1, A = 1 and CY = 0) based on their observed baseline
covariates Z and short-term endpoint X as Yˆ1i = h1(Xi,Zi, ηˆ),
3. then, regress the combination of these fitted values for the treated patients in cohort 2 and the
observed Y values for the treated patients in cohort 1 (Y ∗ := CY Y + (1−CY )CX Yˆ1) on the
baseline covariates Z using a canonical generalized linear working model for the conditional
mean of Y ∗: E(Y ∗|A = 1,Z) = f1(Z, δ0), where f1(Z, δ) is a known function, evaluated at
a parameter δ with unknown population value δ0; for example f1(Z, δ) = logit−1(δ1 + δ2Z),
3
4. and use this regression model to predict Y for the treated patients in cohort 3 based on their
observed baseline covariates Z as Yˆ ′1i = f1(Zi, δˆ).
An interim estimator µˆ1 of P1 is obtained by taking the average of the observed Y -values for the
treated patients in cohort 1, the predicted values Yˆ1i based on Xi and Zi for the treated patients in
cohort 2 and the predicted values Yˆ ′1i based on Zi for the treated patients in cohort 3. A theoretical
derivation of this estimator and its properties are given in Appendix A. The interim estimator µˆ0
for the outcome under control can be analogously estimated by applying the same steps to the
untreated patients A = 0. If the study design does not intend to collect an earlier measurement X,
the first two steps can be omitted since there are then no patients in cohort 2. Y ∗ in step 3 then
reduces to CY Y ; this then involves fitting a model for Y given Z among the (un)treated patients
in cohort 1.
As a result of the random recruitment and simple randomisation, the estimators µˆ1 and µˆ0
have the appealing feature that misspecification of the outcome models in step 1 and 2 does not
introduce bias in large samples (see Appendix A.2). Moreover, when the outcome models are
correctly specified, these estimators are asymptotically efficient in the subclass of estimators that
are unbiased as soon as (A, CZ), CX and CY are independent of respectively Z, (Z, X) and (Z,
X, Y ) (e.g. , Yang and Tsiatis, 2001; Tsiatis, 2006; Moore and van der Laan, 2009; Stallard, 2010;
Qian, 2018).
In order to calculate the variance of the treatment effect µˆ1−µˆ0, one must take into account that
the predictions are estimated based on particular outcome regression models. It is therefore not
sufficient to compute the variance of the predictions and observed values of the primary endpoint.
In Appendix A.3, we show that this can be easily accommodated under randomization and random
recruitment by calculating the asymptotic variance of µˆ1−µˆ0, denoted s2, as 1/n′ times the sample
variance of the values
(Ai/pˆi)[{CYi CXi /(pˆiY pˆiX)}(Yi − Yˆ1i) + (CXi /pˆiX)(Yˆ1i − Yˆ ′1i) + Yˆ ′1i − µˆ1]
−((1−Ai)/(1− pˆi))[{CYi CXi /(pˆiY pˆiX)}(Yi − Yˆ0i) + (CXi /pˆiX)(Yˆ0i − Yˆ ′0i) + Yˆ ′0i − µˆ0],
(1)
with pˆi = Pˆ (A = 1) the observed randomization probability, pˆiX = Pˆ (CX = 1) and pˆiY = Pˆ (CY =
1|CX = 1) and n′ denoting the total number of recruited patients at the time of the interim
analysis. We refer the interested reader to Appendix A.3 for more details.
2.2.1 Precision Gain based on Baseline Covariates and Short-Term Endpoints
As mentioned before, in large samples, our proposed estimator is never outperformed by the stan-
dard analyses that use only information on the short-term and/or primary endpoint. The proposed
estimator also reduces to these standard analyses if no baseline covariates are available. The mag-
nitude of the precision gain itself depends on different characteristics of the interim analysis and
available data. First, the predictivity of the short-term endpoints and baseline covariates plays a
very important role: the more predictive they are, the more information available, and thus, the
larger the gain in efficiency relative to respectively the standard analyses that use only information
on the primary endpoint and standard analyses that use only information on the primary and
short-term endpoint. Nonetheless, adjusting for a prognostic baseline covariate alone always leads
to larger precision gain than adjusting for an equally prognostic short-term outcome alone because
of the larger number of partially observed patients (cohort 1 and 2) compared to the number
of patients in cohort 2 only (Qian et al , 2016). Second, the recruitment rate and the time at
which the interim analysis is conducted, are also of great value since they influence the number
of patients in each cohort. For example, the relative benefit that results from incorporating base-
line covariates and short-term endpoints is generally smaller at later interim analyses since more
primary endpoint data Y are then available. Lastly, the time at which the short-term endpoint
is measured, is crucial. Assuming two equally predictive short-term endpoints, adjusting for the
earliest measured endpoint will be more advantageous since it will be measured for more patients
relative to adjusting for the one measured later in time.
4
3 Interim Analysis
3.1 Futility stopping Based on Conditional Power
To calculate conditional power, we need to define how far through the trial we are at the time of
the interim analysis. This can be expressed in terms of the information fraction t, which is defined
as the fraction of information available at the time of the interim analysis versus the expected
information at the end of the study; i.e. the fraction of the expected variance of the treatment
effect estimator at the end of the study versus the variance of the interim estimator. Define Zt and
Z1 as the Z-statistic of the treatment effect at information fraction t and at the end of the trial,
respectively, and let A |= B for random variables A and B denote that A is independent of B. For
any test satisfying the independent increments property, i.e.
√
tZt |= (Z1 −
√
tZt), the conditional
power can be computed using the Brownian motion structure in combination with the B-value
(Lan and Wittes, 1988), which is defined as Bt = Zt
√
t, 0 < t ≤ 1:
CPt(θ) = 1− Φ
(
z1−α − Zt
√
t− θ(1− t)√
1− t
)
,
with θ the assumed drift parameter. This parameter reflects the expected Z-score at the final
analysis based on the assumption made about the data to be observed in the remainder of the
study, e.g. θ = z1−α + z1−β when the effect size used for powering the study is used as assumption
for the remaining (unobserved) primary endpoint data. To decide whether or not to stop for
futility, the conditional power is compared to some threshold. If the conditional power is below
this threshold, the trial is stopped for futility; otherwise the trial is continued.
The traditional conditional power approach uses a test statistic based on the treatment-specific
sample averages at the time of the interim analysis
∑n
i=1 C
Y
i AiYi/
∑n
i=1 C
Y
i Ai and
∑n
i=1 C
Y
i (1−
Ai)Yi/
∑n
i=1 C
Y
i (1− Ai), which only use the complete cases (i.e., CYi = 1). It seems appealing to
employ instead the interim test statistic based on the more efficient estimator introduced in the
previous section
Zt =
µˆ1 − µˆ0√
s2
,
which also incorporates information on the short-term outcome and the baseline covariates. Note
that the test statistic for the primary analysis (at the end of the study), Z1, coincides with the
standard Z test statistic which only incorporates information on the primary endpoint. Since
the conditional power is computed using standard Brownian motion arguments, the independent
increments property needs to be satisfied. A potential concern is that the additional information
accrued between the interim analysis and the final analysis involves additional observations of
subjects who already contributed information to the interim analysis. Building on Scharfstein et
al. (1997), we show in Appendix B that the independent increments assumption is nonetheless
(asymptotically) maintained when the prediction models are correctly specified since our test is
then semiparametric efficient. Interestingly, we show in Appendix B that this is even true when
the prediction models are misspecified, assuming that the treatment is randomly assigned and the
recruitment is random.
The information fraction t is now calculated as the fraction of the variance of the estimator
at the end of the study and the variance s2 of the interim estimator µˆ1 − µˆ0. This is not readily
available since at the time of the interim analysis, the variance of the final estimator is unknown
as Y is only available for the patients in cohort 1 (CYi = 1). Nevertheless, under the assumption of
random recruitment, Y |= CY , the variance of the final estimator can be estimated using only the
complete cases since they then form a representative sample. This allows estimating the variance
as 1/n times the sample variance of (Ai/pˆi)(Yi − µˆ1)− {(1−Ai)/(1− pˆi)}(Yi − µˆ0) in cohort 1.
3.2 Sample Size Reassessment Based on Conditional Power
When the trial is not stopped early for futility at the interim analysis, one may still consider
modifying the sample size based on the unblinded treatment effect. After sample size adaptations,
the usual test statistic at the end of the study, which simply pools the outcome data obtained
before and after the sample size adjustment, cannot be applied since its naive use might inflate the
type I error rate (Bretz et al. , 2009). The adaptive p-value combination test proposed by Bauer
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(1989) and Bauer and Köhne (1994) allows to combine the independent test statistics Z(1) and Z(2)
based on the data observed before (stage 1) and after (stage 2) the interim analysis, respectively,
while guaranteeing Type I error rate control. Moreover, this two stage procedure corresponding
with the combination test provides a simple way for sample size reassessment.
The combination test for the final analysis can be obtained with the weighted inverse normal
combination function (Lehmacher and Wassmer, 1999), which can be written as
C(Z(1), Z(2)) = 1− Φ(√wZ(1) +√1− wZ(2)),
where Φ denotes the standard normal cumulative distribution function, and w a pre-specified
weight which can be chosen arbitrarily between 0 and 1. It follows from Lehmacher and Wassmer
(1999) that, no matter the choice of weight w, rejecting the null hypothesis when C(Z(1), Z(2)) < α,
leads to a test at level α when Z(1) and Z(2) are independent. A natural choice for the weight w is
the originally planned information fraction t at which the interim analysis is performed, since the
inverse normal combination test using normally distributed test statistics then coincides with a
group sequential design test statistic at the final analysis when sample size remains as pre-planned
[23]. The interim test statistic Zt is used as the test statistic corresponding with the first stage,
since it is based on all data observed before the interim analysis. Now, define Z˜1 as the naive
standard (unweighted) test statistic for the primary endpoint at the end of the trial after sample
size re-estimation and t˜ as the fraction of information available at the interim analysis relative to
the information available at the end of the study after sample size re-assessment; i.e. the fraction of
the variance of the treatment effect estimator at the end of the trial after sample size re-estimation
versus the variance of the interim estimator. We propose Z(2), the test statistic based on the data
to be observed in the remainder of the study, to equal (Z˜1−
√
t˜Zt)/
√
1− t˜, which is asymptotically
independent of Zt (see Appendix B and C.1) and guarantees that
√
tZ(1) +
√
1− tZ(2) equals Z˜1
if there are no adaptations. In particular, the proposed adaptive combination test can be written
as
C(Z(1), Z(2)) = 1− Φ
(√
tZt +
√
1− t Z˜1 −
√
t˜Zt√
1− t˜
)
.
Using this combination test makes it possible to perform a sample size reassessment during the
course of the trial. The total sample size is adapted so as to make the conditional power equation
equal to the pre-specified design power of 1 − β, assuming the effect size used for powering the
study for the remaining (unobserved) primary endpoint data (Bauer and König, 2006). Based
on the principle that the a priori fixed weights derived from the planned information fraction at
the interim analysis are used for the calculation of the final test-statistics, rearrangement of the
formulae of Bauer and König (2006) (see Appendix C.2) leads to
n˜− t · n =
 z1−α−Zt√t√1−t − zβ
θ/
√
n
2 , (2)
where n˜ corresponds to the total sample size after adaptation. Note that z1−α−Zt
√
t√
1−t −zβ < 0 points
to the fact that the new experimental treatment is significantly better and no further recruitment is
needed. Considering that the total sample size is bounded to equal at least the number of recruited
patients at the interim analysis, we then obtain
n˜ = max
n′,
max
(
0, z1−α−Zt
√
t√
1−t − zβ
)
θ/
√
n
2 + t · n
 , (3)
with n′ the total number of patients recruited at the interim analysis. If a sample size decrease
is not allowed, the new sample size is obtained by taking the minimum of n and the second part
in formula (3). In practice, sample size reassessment may be done carrying forward the observed
treatment effect instead of the effect size used for powering the study, by replacing θ in the previous
formulas by Zt/
√
t.
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3.3 Blinded Information Fraction
Usually, the interim analysis is implemented at the time at which the pre-planned information
fraction t is reached. Calculating this information fraction can be either done in a blinded or
unblinded way. Unblinding the treatment assignment code, however, requires an independent
data monitoring committee to review the accumulating data from the beginning of the trial. We
therefore recommend to approach the operational planning alternatively, in a way that preserves
blinding. As before, one can calculate the information fraction in a blinded way by estimating the
fraction of the variances of the treatment effect estimator at the end of the study versus during
monitoring of the trial. The estimates of the two variances should now be based on the blinded
data, without making use of the observed data on treatment. Under the null hypothesis (Yi |= Ai)
and the assumption that Yi |= CYi , the variance of the estimator for the treatment effect at the
end of the study can be blindly estimated as 1/(n(1 − pˆi)pˆi) times the sample mean of (Y − µˆ)2
over all patients in cohort 1, with µˆ =
∑n
i=1 C
Y
i Yi/
∑n
i=1 C
Y
i (see Appendix D). Assuming that
CXi |= Yi|Zi and CYi |= Yi|Zi, Xi, CXi = 1, the blinded estimate of s2, the variance of the estimator
for the treatment effect during monitoring the trial, is obtained by following the same steps as in
Section 2.2 but supposing now that everyone is in the same group. Formulas and their derivation
are included in Appendix D.
4 Simulation Study
We conducted a simulation study to examine the finite-sample performance of the proposed in-
terim estimator for making early decisions based on the conditional power approach as well as for
reassessing the sample size. The impact of the short-term endpoint and baseline covariates on the
one hand and model misspecification on the other were investigated. We evaluate the expected
total number of subjects, the expected number of subjects needed at the interim analysis, as well
as the type 1 error and power.
4.1 Data Generating Distributions for Simulation Studies Based on TMC207-
C208 Stage 2
To determine a realistic data generating model, the phase 2b data of the motivating example
were employed. This dataset consists of 132 participants, 66 in each arm, with observed primary
endpoint data. We generate a simulated trial of n -depending on the simulation settings- hypo-
thetical participants using the original dataset as follows. We resample with replacement from
the original study population of 132 patients and only extract the baseline covariate information
from the subjects in the resampled population. Then, treatment and control are assigned with
probability 0.5 to each hypothetical participant. The short-term endpoint X, measured 4 months
after randomization, is predicted based on a Bernoulli distribution with probability determined by
a logistic regression model for X fitted on the original phase 2b dataset. The primary endpoint
data, measured 15 months after randomization, are generated under different scenarios depending
on the simulation study. Unless otherwise stated, we consider the same recruitment scenario as in
the phase 2b dataset, where on average 8 patients per month enter the study.
Respectively 2, 500 and 10, 000 (100, 000 for futility scenarios) Monte Carlo simulations were
performed for the different settings evaluating the proposal for the conditional power approach and
the sample size reassessment. The cut-off values to decide whether or not to stop for futility at
the interim analysis are based on the O’Brien-Fleming futility boundaries assuming a total power
of 0.90 and a one-sided α = 0.025 (see [25]).
4.2 Simulations on Conditional Power
4.2.1 Without Short-Term Measurements
First, we conducted a simulation study to show that the conditional power based on the proposed in-
terim estimator outperforms the standard conditional power approach when adjusting for predictive
baseline covariates. For pedagogic purposes, only one continuous covariate Z1 that might be pre-
dictive for cure was selected based on the phase 2b data. The resulting model -allowing for different
degrees of predictivity- was employed to simulate the primary endpoint data for each subject i (i =
1, · · · , n), Yi|Zi d= Ber{m0(Zi)}, where m0(Z) = logit−1(−0.23 + 0.75A+ c · 0.39Z1 + c · 0.17Z1A)
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with c ∈ {0, 1, 2, 3, 4, 5} and the coefficients {−0.23, 0.75, 0.39, 0.17} correspond to these obtained
from a logistic regression of Y on the continuous covariate Z1 fitted on the original data. The
proportion of the variance in Y that is predictable from Z = Z1 is shown in Table 1 (see Appendix
E). The sample size of 227 patients in each arm corresponds with the required sample size to obtain
Table 1: Empirical R-squared values and probability of succes (under alternative hypothesis) for
the data generated under the settings without short-term endpoint. Simulations results are based
on 10, 000 Monte Carlo replications.
H0 H1
A = 1 A = 0 A = 1 A = 0
Model R2 R2 R2 R2 P1 P0
c = 0 0.01 0.01 0.01 0.01 0.63 0.44
c = 1 0.07 0.07 0.12 0.07 0.62 0.44
c = 2 0.20 0.20 0.34 0.20 0.60 0.45
c = 3 0.36 0.36 0.54 0.36 0.57 0.45
c = 4 0.50 0.50 0.67 0.50 0.55 0.45
c = 5 0.61 0.61 0.76 0.61 0.54 0.45
Note: R2 corresponds with the proportion of the variance in Y that is predictable
from Z = Z1 (estimated using formulas in Appendix E); P1 and P0, probability
of success in respectively the treatment and control arm under superiority.
a power of 0.90 under a one-sided significance level of 0.025 for the scenario with c = 2. Note that
fixing the sample size implies a different power under each setting ({0.98, 0.97, 0.90, 0.76, 0.61, 0.47}
for c = {0, 1, 2, 3, 4, 5}) since the different scenarios resemble different treatment effects (P1 − P0
in Table 1).
First, the interim analysis is conducted at the fixed point in time when 75% of the patients are
expected to be recruited (231 patients in cohort 1, 80 patients in cohort 2, 29 patients in cohort 3).
In Figure 1, the proposed conditional power approach incorporating baseline covariates is compared
with standard conditional power for the different scenarios under true futility and true superiority,
respectively. A comparison between both methods shows that incorporating baseline covariates
leads to a free upgrade: a higher information fraction as well as a higher probability to stop for
true futility (Figure 1a) are obtained with negligible loss of power (Figure 1b). The former is a
consequence of the higher cutoff value corresponding with a higher information fraction. Also note
that, in general, a lower power (corresponding with higher c and R20) implies a higher probability
to stop incorrectly for futility and a slightly higher power loss. Comparing the different scenarios,
shows that more predictive baseline covariates induce an increase in the information fraction and
the probability to correctly stop for true futility. This is due to the efficiency gain from adjusting
for baseline variables [18].
Second, an interim analysis is conducted when 50%1 of the information in the simulated datasets
is obtained in order to evaluate the time gain compared to the standard conditional power. Table 2
shows that this information fraction is obtained earlier for the proposal, resulting in fewer recruited
patients at the time of the interim analysis. Moreover, when using the proposed method, more
predictive covariate(s) (higher c) lead to an earlier implementation of the interim analysis. The
upper part of the table shows that the probability to stop incorrectly for futility as well as the loss
of power is comparable between the two methods, while in the lower part it can be seen that the
probability to stop correctly for true futility is similar. Thus, by using the proposal, fewer patients
need to be recruited to make a decision with the same probability to correctly stop for true futility
and with the same loss of power as with the standard method (power loss < 1%).
As can be seen in Figure 2, conducting the interim analysis at different information fractions
leads to similar absolute reductions in number of recruited patients. Therefore, the relative gain,
defined as the difference in number of recruited patients between both methods relative to the
1This information fraction is determined based on Y only for the standard conditional power and based on Z,
X and Y for the proposed method.
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Table 2: Comparison of the standard conditional power approach and the conditional power using
the proposed interim estimator when the interim analysis is conducted at an information fraction
of 50%. Upper table: results under superiority; Lower table: results under futility.
Model Method # Days % Recruited Prob. to Stop Power Loss
c = 0
Proposal 1288 74% 0.6% 0.24%
Standard CP 1294 74% 0.5% 0.16%
c = 1
Proposal 1275 73% 0.8% 0.48%
Standard CP 1294 74% 0.8% 0.44%
c = 2
Proposal 1243 72% 2.2% 0.96%
Standard CP 1294 74% 2.5% 0.88%
c = 3
Proposal 1207 69% 5.4% 0.92%
Standard CP 1294 74% 5.9% 1.00%
c = 4
Proposal 1173 68% 9.6% 0.88%
Standard CP 1294 74% 9.7% 0.92%
c = 5
Proposal 1144 66% 13.3% 0.88%
Standard CP 1294 74% 13.6% 0.92%
Model Method # Days % Recruited Prob. to Stop
c = 0
Proposal 1289 74% 59.9%
Standard CP 1294 74% 60.4%
c = 1
Proposal 1279 74% 59.4%
Standard CP 1294 74% 59.2%
c = 2
Proposal 1253 72% 59.0%
Standard CP 1294 74% 59.6%
c = 3
Proposal 1222 70% 59.9%
Standard CP 1294 74% 60.1%
c = 4
Proposal 1191 69% 60.1%
Standard CP 1294 74% 60.0%
c = 5
Proposal 1164 67% 59.6%
Standard CP 1294 74% 60.0%
Note: # Days, average number of days elapsed since beginning of the study; % Recruited,
average percentage of patients already recruited; Prob. to Stop, probability to stop for
futility using O’Brien Fleming boundaries; Power Loss, loss of power when conducting an
interim analysis compared to the design power.
number of recruited patients using the standard conditional power, increases with decreasing infor-
mation fraction. Another determining factor is the average number of monthly recruited patients.
We therefore simulated 2, 500 datasets under the futility scenario with c = 2 for a recruitment rate
of 16 patients a month instead of 8. The percentage of recruited patients at information fraction
0.30 is 78% and 73% for the standard and proposed conditional power, respectively, corresponding
with a relative gain of 6%. For a recruitment rate of 8 patients a month, these equal 55% and
52%, respectively, corresponding with a relative gain of 4%. The reduction in number of recruited
patients is thus larger for faster recruitment settings.
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4.2.2 With Short-Term Measurements
To also incorporate short-term measurements along with three baseline covariates, the follow-
ing data-generating mechanism Yi|Xi,Zi d= Ber{m0(Xi,Zi)} (i = 1, · · · , n) was employed, with
m0(X,Z) predictions from a logistic regression model for Y involving the 2-way interaction be-
tween A and X, the 3-way interaction between A, a continuous covariate Z1 (same as in Section
4.2.1) and a dichotomous covariate Z2, the 3-way interaction between A, a continuous covariate Z1
(same as in Section 4.2.1) and a 3-level covariate Z3, and all lower order terms. Under this data-
generating model, the marginal probabilities of success in the control and experimental treatment
arm are 0.60 and 0.49, respectively. To attain 90% power at a one-sided significance level of 2.5%,
421 patients in both arms are required.
Simulation experiments with a correctly specified outcome model used the working models
h1(X,Z,η) = logit−1(η1 + η2X + η3Z1 + η4Z2 + η5Z3 + η6Z1Z2 + η7Z1Z3) and h0(X,Z, ζ) =
logit−1(ζ1 + ζ2X + ζ3Z1 + ζ4Z2 + ζ5Z3 + ζ6Z1Z2 + ζ7Z1Z3) to predict the missing outcomes in
cohort 2 and working models f1(Z, δ) = logit−1(δ1 + δ2Z1 + δ3Z2 + δ4Z3 + δ5Z1Z2 + δ6Z1Z3)
and f0(Z,ν) = logit−1(ν1 + ν2Z1 + ν3Z2 + ν4Z3 + ν5Z1Z2 + ν6Z1Z3) to predict the missing
outcomes in cohort 3. To evaluate the performance when the prediction models are misspecified
and to investigate whether this could lead to incorrectly stopping, we also considered the following
outcome working models
1. a misspecified model including X, Z1, Z2 and Z3 but without interactions; h1(X,Z,η) =
logit−1(η1+η2X+η3Z1+η4Z2+η5Z3) and h0(X,Z, ζ) = logit−1(ζ1+ζ2X+ζ3Z1+ζ4Z2+ζ5Z3)
to predict the missing outcomes in cohort 2 and f1(Z, δ) = logit−1(δ1 + δ2Z1 + δ3Z2 + δ4Z3)
and f0(Z,ν) = logit−1(ν1 + ν2Z1 + ν3Z2 + ν4Z3) to predict the missing outcomes in cohort
3;
2. a model only including X and Z1; h1(X,Z,η) = logit−1(η1+η2X+η3Z1) and h0(X,Z, ζ) =
logit−1(ζ1 + ζ2X + ζ3Z1) to predict the missing outcomes in cohort 2 and f1(Z, δ) =
logit−1(δ1 + δ2Z1) and f0(Z,ν) = logit−1(ν1 + ν2Z1) to predict the missing outcomes in
cohort 3;
3. a misspecified model including X and the absolute value of Z1; h1(X,Z,η) = logit−1(η1 +
η2X + η3|Z1|) and h0(X,Z, ζ) = logit−1(ζ1 + ζ2X + ζ3|Z1|) to predict the missing outcomes
in cohort 2 and f1(Z, δ) = logit−1(δ1+δ2|Z1|) and f0(Z,ν) = logit−1(ν1+ν2|Z1|) to predict
the missing outcomes in cohort 3;
4. a model only including X and Z3; h1(X,Z,η) = logit−1(η1+η2X+η3Z3) and h0(X,Z, ζ) =
logit−1(ζ1 + ζ2X + ζ3Z3) to predict the missing outcomes in cohort 2 and f1(Z, δ) =
logit−1(δ1 + δ2Z3) and f0(Z,ν) = logit−1(ν1 + ν2Z3) to predict the missing outcomes in
cohort 3.
The expected Y values for outcome working models 2 and 3 as well as for the correctly specified
model are plotted against Z1 in Figure 3. To compare our proposal to methods only using X
(e.g. Niewczas et al. , 2016), outcome working models only including X were used. Note that, in
that case, we don’t predict the outcome for the patients in cohort 3. The proportion of the variance
in Y that is related to Z = {Z1, Z2, Z3}, X and both under these different prediction models is
shown in Table 3.
First, the interim analysis is conducted at the fixed point in time when 75% of the patients
are expected to be recruited (407 patients in cohort 1, 164 patients in cohort 2, 60 patients in
cohort 3). Table 4 shows that a higher total R2 (see Table 3) and the use of correctly specified
working models, lead to a higher information fraction and a higher probability to correctly stop for
true futility. This is again due to the efficiency gain from adjusting for (more predictive) baseline
variables and short-term endpoints ([18]).
When conducting an interim analysis at the time 50% of the information is obtained, the advan-
tage over the standard conditional power increases with increasing total R2, while the advantage
over the method only using X is mainly determined by R2Z . The latter is a consequence of the fact
that the proposal also incorporates baseline covariates on top of the short-term endpoint. However,
in this simulation study there are on average only 60 patients in cohort 3 compared to 164 in cohort
2 and 387 in cohort 1. Therefore, the relative advantage over the method only using X compared
to the advantage of the latter over the standard method, is rather limited. The relative gain will
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Table 3: Empirical R-squared values for the data generated under the settings for the conditonal
power with short-term endpoint measurements. Simulations results are based on 10, 000 Monte
Carlo replications.
A = 1
H0 H1
Model R2Z R
2
X R
2 R2Z R
2
X R
2
Correct 0.27 0.34 0.61 0.28 0.72 1
Misspecified (1) 0.11 0.40 0.52 0.09 0.66 0.74
Misspecified (2) 0.02 0.40 0.42 0.06 0.66 0.72
Misspecified (3) 0.004 0.39 0.40 0.004 0.71 0.72
Misspecified (4) 0.10 0.39 0.48 0.01 0.71 0.72
Only X 0 0.39 0.39 0 0.71 0.71
Note: R2Z , R2X and R2 correspond to the proportion of the variance in
Y that is predictable from respectively Z = {Z1, Z2, Z3}, X and both Z
and X; estimated using formulas in Appendix E.
increase when cohort 3 contains proportionately more patients. To see this, we conducted a sim-
ulation study where the short-term endpoint is measured 12 months after randomization instead
of 4 months, corresponding with an average of 404 patients in cohort 1, 75 in cohort 2 and 149 in
cohort 3. The percentage of recruited patients is then given by 77%, 75% and 72% for respectively
the standard conditional power, the conditional power only including the short-term endpoint X
and our proposal. The absolute advantage (3%) of including both baseline covariates and the
short-term endpoint over the method only incorporating the short-term endpoint is similar as for
X measured 4 months after randomization. The gain in terms of percentage recruited patients
at the time of the interim analysis by incorporating baseline covariates on top of the short-term
endpoint relative to the gain by only incorporating the short-term endpoint increases from 1.6
(= (77 − 69)/(77 − 72)) to 2.5 (= (77 − 72)/(77 − 75)), meaning that the decrease in number of
recruited patients compared to the standard conditional power is respectively 1.6 and 2.5 times
larger for the proposal than for the conditional power only including X and Y .
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Table 4: Comparison when the interim analysis is conducted at the fixed point in time where 75%
of the patients are recruited. Upper table: results under superiority; Lower table: results under
futility.
Method t Prob. to Stop Power Loss
#Cohort 1 = 407, #Cohort 2 = 164, #Cohort 3 = 60
Proposal, correct 0.58 3.3% 0.84%
Proposal, misspecified (1) 0.56 3.0% 0.92%
Proposal, misspecified (2) 0.54 2.8% 0.76%
Proposal, misspecified (3) 0.54 3.0% 0.80%
Proposal, misspecified (4) 0.55 2.9% 0.80%
Proposal, only X 0.54 3.0% 0.80%
Standard CP, only Y 0.48 1.8% 0.48%
Method t Prob. to Stop
#Cohort 1 = 407, #Cohort 2 = 164, #Cohort 3 = 60
Proposal, correct 0.56 69.4%
Proposal, misspecified (1) 0.55 68.0%
Proposal, misspecified (2) 0.53 65.1%
Proposal, misspecified (3) 0.53 64.8%
Proposal, misspecified (4) 0.54 67.0%
Proposal, only X 0.53 64.4%
Standard CP, only Y 0.48 56.4%
Note: t, average information fraction; Prob. to Stop, probability to stop for futility using
O’Brien Fleming boundaries; Power Loss, loss of power when conducting an interim analysis
compared to the design power.
4.3 Simulations on Sample Size Re-Estimation
In these simulation studies, futility stopping based on conditional power as well as sample size
adaptations were performed. The total sample size was bounded to be at most 2 times the original
sample size. We generated data under a data-generating mechanism where for each i (i = 1, · · · , n),
Yi|Xi, Ai,Zi d= Ber(m0(Xi, Ai,Zi)), with m0(X,A,Z) = logit−1(ω0 + c ·ω1A+ω2X + c ·ω3XA+
ω4Z1+c·ω5Z1A), c ∈ {0, 0.5, 1, 5, 1.5} and the coeffcients {ω0, . . . , ω5} correspond to these obtained
from a logistic regression fitted on the original phase 2b data. The marginal probabilities of success
in the treatment and control arm under the data-generating model with c = 1 are 0.60 and 0.47,
respectively, corresponding with a treatment effect of 0.13. To attain a power of 0.90 under this
alternative at a one-sided significance level of 0.025 the required sample size in both treatment arms
is 319 patients. The other probabilities of success in the treatment arm are 0.47, 0.56 and 0.63 for
c = 0, c = 0.5 and c = 1.5, respectively, corresponding with a treatment effect of respectively 0,
0.09 and 0.16, respectively.
Table 6 shows the results for a simulation study where the interim analysis is conducted at
the fixed point in time where 478 out of the planned 638 patients, corresponding with 75%, are
recruited. We can see that in all cases the type I error rate is controlled, since the power after
sample size reassessment is around 2.5% for a treatment effect equal to 0. As before, the information
fraction as well as the probability to stop for true futility are higher for the proposal. However,
this also causes a slightly larger loss in power relative to the standard approach. When sample
size re-assessment is performed, there is an increase in power for both methods compared to the
designs without sample size reassessment and the classical one-stage trial, except for a treatment
effect equal to 0.16. On average a smaller sample size is needed for the proposal, but this comes
with a lower overall power over the two stages. The lower sample size causes a higher probability
to be unsuccessful after sample size reassessment for a trial that is not stopped for futility and
successful without sample size reassessment, which results in a lower power.
The results for the simulation study where the interim analysis is conducted when 50% of the
total information is obtained, are summarised in Table 7 in Appendix F. The probability to stop
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Table 5: Comparison when the interim analysis is conducted at an information fraction of 50%.
Upper table: results under superiority; Lower table: results under futility.
Method # Days % Recruited Prob. to Stop Power Loss
Proposal, correct 1066 67% 2.3% 0.44%
Proposal, misspecified (1) 1101 69% 2.4% 0.60%
Proposal, misspecified (2) 1119 71% 2.2% 0.52%
Proposal, misspecified (3) 1124 71% 2.1% 0.52%
Proposal, misspecified (4) 1111 70% 2.2% 0.52%
Proposal, only X 1126 71% 2.1% 0.56%
Standard CP, only Y 1217 77% 2.0% 0.48%
Method # Days % Recruited Prob. to Stop
Proposal, correct 1096 69% 60.3%
Proposal, misspecified (1) 1116 70% 60.0%
Proposal, misspecified (2) 1142 72% 59.1%
Proposal, misspecified (3) 1145 72% 59.9%
Proposal, misspecified (4) 1124 71% 59.2%
Proposal, only X 1146 72% 59.7%
Standard CP, only Y 1217 77% 59.3%
Note: # Days, average number of days elapsed since beginning of the study; % Recruited,
average percentage of patients already recruited; Prob. to Stop, probability to stop for futility
using O’Brien Fleming boundaries; Power Loss, loss of power when conducting an interim
analysis compared to the design power.
for futility and the power loss when no sample size reassessment is performed are more comparable
in this simulation study, but generally the results are similar for the setting where the interim
analysis is conducted at a fixed point in time.
Doing a sample size reassessment after performing an interim analysis thus seems to be equally
beneficial for both methods; resulting in (slightly) lower sample sizes at a cost of (slightly) lower
overall power for the proposal compared to the standard method. Given the lower total sample
size and lower number of patients recruited at the time of the interim analysis compared to the
standard method, it seems advantageous to use the proposal, even with the cost of a (slightly)
lower power.
5 Discussion
In this paper, we propose a method to efficiently exploit all information available on baseline covari-
ates as well as short-term endpoint data (e.g. an assessment of the primary endpoint at an earlier
time) to improve decision-making as well as sample size reassessment at an interim analysis. Our
proposal assumes that the observed association between the primary endpoint and the short-term
endpoint and the observed association between the primary endpoint and the baseline covariates
do not change over time. The plausibility of this assumption, which can often be expected to hold
under random recruitment, should be assessed a priori based on consultation with clinicians. In
contrast to competing approaches using surrogate endpoints (e.g. , Prentice, 1989), the estimand
that we consider at the interim analysis is the treatment effect on the final endpoint, rather than
on the short-term endpoint. This has the advantage that no assumptions are needed on the extent
to which the short-term endpoint is a good surrogate for the final endpoint. It moreover enables
one to better judge the clinical significance of the interim results. It has the drawback, however,
that data will be needed on patients who have completed the study, even at the interim assessment.
Our proposed estimator has the appealing feature that model misspecification does not intro-
duce bias, but it may reduce efficiency compared to a correctly specified prediction model. Despite
this precision loss, our proposed estimator is never outperformed by the standard analyses that
only use information on the short-term and primary endpoint since the proposed estimator reduces
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Table 6: Operating characteristics of a trial with sample size re-assessment based on conditional
power as futility stopping rule at the fixed point in time where 478 out of the planned 638 patients
are recruited. Results are based on 5000 Monte Carlo simulations.
Treatment Effect
0 0.09 0.13 0.16
Power One Stage Trial 2.52% 57.78% 90.66% 98.70%
Proposal Average t 0.46 0.47 0.48 0.49
Probability to Stop for Futility 50.0% 8.0% 1.9% 0.4%
Power Loss 0.04% 0.65% 0.76% 0.19%
Power No SSR 2.47% 57.13% 89.90% 98.51%
Q0 No SSR 478 478 478 478
Q1 No SSR 478 638 638 638
Q2 No SSR 478 638 638 638
Q3 No SSR 638 638 638 638
Q4 No SSR 638 638 638 638
ASS No SSR 557(80) 625(43) 635(22) 637(9)
Power SSR 2.51% 73.75% 93.96% 98.62%
Q0 SSR 478 478 478 478
Q1 SSR 478 478 478 478
Q2 SSR 478 872 484 478
Q3 SSR 1276 1276 964 510
Q4 SSR 1276 1276 1276 1276
ASS SSR 837(389) 890(359) 715(320) 581(230)
% Rejected with SSR, not without 2.7% 59.6% 82.8% 93.0%
% Not rejected with SSR, rejected without 50.0% 7.3% 3.0% 1.0%
Standard CP Average t 0.41 0.41 0.41 0.41
Probability to Stop for Futility 38.6% 4.87% 1.13% 0.19%
Power Loss 0.04% 0.45% 0.42% 0.09%
Power No SSR 2.50% 57.33% 90.24% 98.61%
Q0 No SSR 478 478 478 478
Q1 No SSR 478 638 638 638
Q2 No SSR 638 638 638 638
Q3 No SSR 638 638 638 638
Q4 No SSR 638 638 638 638
ASS No SSR 576(78) 630(34) 636(17) 638(7)
Power SSR 2.63% 75.12% 95.65% 99.07%
Q0 SSR 478 478 478 478
Q1 SSR 478 478 478 478
Q2 SSR 1276 971 508 478
Q3 SSR 1276 1276 1145 554
Q4 SSR 1276 1276 1276 1211
ASS SSR 924(386) 917(357) 742(335) 605(256)
% Rejected with SSR, not without 2.2% 56.0% 83.3% 88.3%
% Not rejected with SSR, rejected without 46.4% 5.9% 2.0% 0.6%
Note: Power One Stage Trial, a reference power of one stage trial where no interim analyses or adaptations are
conducted; Average t, average time fraction; FS, probability to stop for futility using O’Brien Fleming boundaries;
Power Loss, loss of power when conducting an interim analysis compared to the design power; Power SSR/No SSR,
Power when there is/is no sample size re-assessment; Qi SSR/No SSR, ith quantile of the sample size when there is/is
no sample size re-assessment; ASS SSR/No SSR, average sample size over both stages and its standard deviation (in
brackets); % Rejected with SSR, not without, proportion of trials that were not stopped and not rejected without SSR
that are rejected with SSR; % Not rejected with SSR, rejected without, proportion of trials that were not stopped and
rejected without SSR that are not rejected with SSR.
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to these standard analyses if no baseline covariates are available. Moreover, when the models are
correct, the resulting estimator is asymptotically efficient in the subclass of estimators that have
this robustness. Implementing the interim test statistic based on the proposed estimator in the
conditional power approach therefore allows earlier stopping for true futility whilst controlling the
probability for incorrectly stopping, resulting in fewer recruited patients. Additionally, sample
size reassessment based on conditional power was considered. To guarantee the type I error, the
combination test was applied for the final analysis. In simulation studies, we observed that the
incorporation of information on baseline covariates and short-term endpoints is beneficial in terms
of smaller sample sizes needed to obtain a similar power. A potential concern was that the addi-
tional information accrued between the interim analysis and the final analysis potentially involves
observations of subjects who already contributed information to the interim analysis. Building
on Scharfstein et al. (1997), we have shown that this is not problematic for the considered test
statistic, as it satisfies the independent increments property.
Although the present paper has focused on binary endpoints, the same approach can be used
for continuous and survival endpoints. In future work, we will use repeated measures models that
use information at multiple secondary endpoint times to provide furter efficiency gains.
At early interim analyses, incorporating the most predictive baseline covariate(s) or short term
endpoint(s) may already lead to an important efficiency gain. However, we recommend using in-
creasingly flexible models as more primary endpoint data come available. This because an asymp-
totic efficiency gain is guaranteed upon adding more terms to the model (and thus increasing the
R2) even when the model is not correctly specified.
For simplicity, we have developed our proposal so that the interim analysis coincides with the
standard analysis at the end. However, there is still a high potential to gain efficiency, and thus
reduce the required sample size for the study, by also including baseline covariates in the final
analysis. This can be done by using efficient estimators similar to those discussed in this paper for
the end of study comparison (Tsiatis, 2008).
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Appendix
Appendix A: The Interim Estimator
The focus in this section is on the estimator µˆ1 in the experimental treatment arm, but reasonings
and results are similar for µˆ0 and µˆ1 − µˆ0. The formulas in this section make use of the estimated
unadjusted probabilities pˆi, pˆiX and pˆiY .
Appendix A.1: Theoretical Derivation of the Interim Estimator
Let µ1 = E(Y |A = 1) and consider the problem of estimating µ1 using the observed data. Under
the non-parametric model for the data (A, Y , X, Z), all RAL estimators of µ1 have influence
function equal to
ϕ(0) = (A/pi)(Y − µ1),
with pi the true randomization probability. Assume that the covariates Z and the treatment
indicator A contain sufficient information to explain the missingness so that the missing at ran-
dom (MAR) assumption, Y |= CX |A,Z (Tsiatis, 2006), holds. Tsiatis (2006) shows that all RAL
estimators of µ1, under the assumption that piX is known, have influence function{
CXϕ(0)
piX
+
(
1− C
X
piX
)
L(1)(A,Z)
}
, (4)
where L(1)(A,Z) is an arbitrary function of A and Z. From Theorem 10.2 in Tsiatis (2006), for
given ϕ(0), the optimal choice for L(1)(A,Z) that leads to a semi-parametric efficient estimator
under the above restrictions is given by E(ϕ(0)|CX = 1, A,Z). Therefore, among the class of
influence functions (4), the one with the smallest variance is
ϕ(1) =
CXϕ(0)
piX
+
(
1− C
X
piX
)
E(ϕ(0)|CX = 1, A,Z)
=
CXA
piXpi
Y +
A
pi
(
1− C
X
piX
)
E(Y |CX = 1, A, Z)− A
pi
µ1.
(5)
Assume that the covariates Z, the treatment indicator A, the missingness indicator CX and the
intermediate endpoint X contain sufficient information to explain the missingness so that the miss-
ing at random (MAR) assumption, Y |= CY |A,Z, CX , X (Tsiatis, 2006), holds. All RAL estimators
of µ1, under the assumption that piY is known, have influence function{
CY ϕ(1)
piY
+
(
1− C
Y
piY
)
L(2)(A,Z, CX , X)
}
, (6)
where L(2)(A,Z, CX , X) is an arbitrary function of A, Z, CX andX. From Theorem 10.2 in Tsiatis
(2006), for given ϕ(1), the optimal choice for L(2)(A,Z, CX , X) that leads to a semi-parametric effi-
cient estimator under the above restrictions is given by E
(
ϕ(1)|CY = CX = 1, A, Z,X). Therefore,
among the class of influence functions (6), the one with the smallest variance is
ϕ(2) =
CY ϕ(1)
piY
+
(
1− C
Y
piY
)
E(ϕ(1)|CY = CX = 1, A, Z,X)
=
CY CXA
piY piXpi
Y +
ACX
pipiX
(
1− C
Y
piY
)
E(Y |CY = CX = 1, A, Z,X)
+
A
pi
(
1− C
X
piX
)
E(Y |CX = 1, A, Z)− A
pi
µ1.
(7)
This suggests estimating µ1 as the solution to the estimating equation
n′∑
i=1
{
CYi C
X
i Ai
pˆiY pˆiX pˆi
Yi +
AiC
X
i
pˆipˆiX
(
1− C
Y
i
pˆiY
)
Yˆ1i
+
Ai
pˆi
(
1− C
X
i
pˆiX
)
Yˆ ′1i −
Ai
pˆi
µ1
}
= 0,
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where n′ is the number of recruited patients at the interim analysis, Yˆ1i = h1(Xi,Zi, ηˆ) with
E(Y |A = 1,Z, X) = h1(X,Z,η0), where h1(X,Z,η) is a known function, evaluated at a parameter
η with unknown population value η0, and Yˆ ′1i = f1(Zi, δˆ) with E(Y ∗|A = 1,Z) = f1(Z, δ0), where
f1(Z, δ) is a known function, evaluated at a parameter δ with unknown population value δ0. This
yields
µˆ1 =
∑n′
i=1
{
CYi C
X
i Ai
pˆiY pˆiX pˆi
Yi +
AiC
X
i
pˆipˆiX
(
1− CYi
pˆiY
)
Yˆ1i +
Ai
pˆi
(
1− CXi
piX
)
Yˆ ′1i
}
∑n′
i=1
Ai
pˆi
= n′−1
n′∑
i=1
{
CYi C
X
i Ai
pˆiY pˆiX pˆi
Yi +
AiC
X
i
pˆipˆiX
(
1− C
Y
i
pˆiY
)
Yˆ1i +
Ai
pˆi
(
1− C
X
i
pˆiX
)
Yˆ ′1i
}
,
since n′pˆi =
∑n′
i=1Ai. An alternative derivation is given in Appendix A.3.
Appendix A.2: Robustness of the Interim Estimator
Under the considered recruiting strategy, we can assume independence of (CY , CX , CZ) and
(X, Z). Moreover, in absence of a time effect, random recruitment makes it quite plausible
that CXi |= Yi|Zi, Ai and CYi |= Yi|Zi, Xi, Ai, CXi = 1. Consequently, pˆiX and pˆiY are consistent
estimators for the conditional probabilities P (CX = 1|A,Z) and P (CY = 1|CX = 1, A,X,Z)
respectively. Additionally, pˆi is a consistent estimator for P (A = 1).
Define the probability limits η∗ = plim(ηˆ) and δ∗ = plim(δˆ), which equal respectively the true
values η0 and δ0 when the working models h1(Z, X;η) and f1(Z; δ) are correctly specified, but
not necessarily otherwise. By the weak law of large numbers and Slutsky’s theorem, µˆ1 estimates
E
[
CY CXA
piY piXpi
Y +
ACX
pipiX
(
1− C
Y
piY
)
h1(X,Z,η
∗) +
A
pi
(
1− C
X
piX
)
f1(Z, δ
∗)
]
=E
[
Y |A = 1, CY = 1, CX = 1]+
E
[
E
{(
1− C
Y
piY
)
h1(X,Z,η
∗)
∣∣∣∣A = 1, CX = 1, X,Z}∣∣∣∣A = 1, CX = 1]+
E
[
E
{(
1− C
X
piX
)
f1(Z, δ
∗)
∣∣∣∣A = 1,Z}∣∣∣∣A = 1]
=E
[
Y |A = 1, CY = 1, CX = 1]
=E [Y |A = 1]
We therefore describe the proposed interim estimator as robust, in the sense that it is consis-
tent even if the outcome models h1(X,Z,η) and f1(Z, δ) for respectively E(Y |A = 1, X,Z) and
E(Y ∗|A = 1,Z) are misspecified (Tsiatis, 2008).
Appendix A.3: Asymptotic Variance of the Interim Estimator
Based on the derivation in Section 2.2, µˆ1 can be written as
µˆ1 =
∑n
i=1Ai
{
CYi Yi + (1− CYi )CXi Yˆ1i + (1− CXi )Yˆ ′1i
}
∑n′
i=1Ai
= n′−1
n′∑
i=1
Ai
pˆi
{
CYi Yi + (1− CYi )CXi Yˆ1i + (1− CXi )Yˆ ′1i
}
,
(8)
since n′pˆi =
∑n′
i=1Ai. To obtain the variance of this estimator, one must take into account that
predicted, and not observed, values Yˆ1i and Yˆ ′1i are used in respectively cohort 2 and 3. By adding
the (weighted) sum of the residual terms n′−1
∑n′
i=1(Ai/pˆi)
(
(1− pˆiX pˆiY )/(pˆiX ˆˆpiY )
)
CXi C
Y
i (Yi−Yˆ1i)
and n′−1
∑n′
i=1(Ai/pˆi)
(
(1− pˆiX)/pˆiX)CXi (Yˆ1i − Yˆ ′1i) in Equation (8), we correct for the estimation
of the parameters in the canonical generalized linear models used to estimate respectively Yˆ1i and
Yˆ ′1i (Tsiatis, 2006). Since we are dealing with canonical generalized linear models, the sum of
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both residuals sum to zero and therefore adding these sums to the equations does not change the
estimators µˆ1. Rearranging the terms yields
µˆ1 = n
′−1
n′∑
i=1
Ai
pˆi
(
CYi C
X
i
pˆiY pˆiX
(Yi − Yˆ1i) + C
X
i
pˆiX
(Yˆ1i − Yˆ ′1i) + Yˆ ′1i
)
.
Since the asymptotic behavior of an estimator is fully determined by its influence function, it
suffices to focus on the influence function when discussing the estimator’s variance. Define
φ1(X,Z;P1,η, δ) =
A
pi
[
CY CX
piY piX
{Y − h1(X,Z,η)}+ C
X
piX
{h1(X,Z,η)− f1(Z, δ)}
+f1(Z, δ)− P1
]
,
where E(Y |A = 1, X,Z) = h1(Z, X;η0) and E(Y ∗|A = 1,Z) = f1(Z; δ0). When the working
models h1(Z, X;η) and f1(Z; δ) are correctly specified, then the probability limits η∗ = plim(ηˆ)
and δ∗ = plim(δˆ) equal respectively η0 and δ0, but not necessarily otherwise. Under the as-
sumption that ηˆ, δˆ, pˆi, pˆiX and pˆiY are the solution to respectively the estimating equations
n′−1
∑n′
i=1Uη(Xi,Zi;η) = 0, n
′−1∑n′
i=1Uδ(Zi; δ) = 0, n
′−1∑n′
i=1Upi(pi) = 0, n
′−1∑n′
i=1UpiX (pi
X) =
0 and n′−1
∑n′
i=1UpiY (pi
Y ) = 0, the influence function (Tsiatis, 2006) is given by
φ˜1(X,Z;P1,η
∗, δ∗) =φ1(X,Z;P1,η∗, δ∗)
− E
{
∂φ1
∂ηT
(X,Z;P1,η
∗, δ∗)
}
E−1
{
∂Uη
∂ηT
(X,Z;η∗)
}
Uη(X,Z;η
∗)
− E
{
∂φ1
∂δT
(X,Z;P1,η
∗, δ∗)
}
E−1
{
∂Uδ
∂δT
(Z; δ∗)
}
Uδ(Z; δ
∗)
− E
{
∂φ1
∂pi
(X,Z;P1,η
∗, δ∗)
}
E−1
{
∂Upi
∂pi
}
Upi
− E
{
∂φ1
∂piX
(X,Z;P1,η
∗, δ∗)
}
E−1
{
∂Upi
∂piX
}
UXpi
− E
{
∂φ1
∂piY
(X,Z;P1,η
∗, δ∗)
}
E−1
{
∂Upi
∂piY
}
UYpi .
These,
E
{
∂φ1
∂ηT
(X,Z;P1,η
∗, δ∗)
}
=E
{
∂h1
∂ηT
(X,Z,η∗)
ACX
pipiX
(
1− C
Y
piY
)}
= 0,
and
E
{
∂φ1
∂δT
(X,Z;P1,η
∗, δ∗)
}
=E
{
∂f1
∂δT
(Z, δ∗)
A
pi
(
1− C
X
piX
)}
= 0,
since the propensity scores piY and piX respectively are guaranteed to be correctly specified under
random recruitment. Next,
E
{
∂φ1
∂pi
(X,Z;P1,η
∗, δ∗)
}
=E
{−A
pi2
(
CY CX
piY piX
(Y − h1(X,Z,η)) + C
X
piX
(h1(X,Z,η)− f1(Z, δ))
+f1(Z, δ)− P1
)}
=E
{−A
pi2
(
h1(X,Z,η)
CX
piX
(
1− C
Y
piY
)
+ f1(Z, δ)
(
1− C
X
piX
)
+
CY CX
piY piX
Y − P1
)}
= 0,
by the fact that the propensity scores piY and piX are guaranteed to be correctly specified under
random recruitment and the fact that
∑n′
i=1(AiC
X
i C
Y
i /(pipi
XpiY ))Yi is an unbiased estimator for
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P1. Finally,
E
{
∂φ1
∂piX
(X,Z;P1,η
∗, δ∗)
}
=E
{−1
piX
(
ACXCY
pipiXpiY
(Y − h1(X,Z,η)) + AC
X
pipiX
(h1(X,Z,η)− f1(Z, δ))
)}
=0,
and
E
{
∂φ1
∂piY
(X,Z;P1,η
∗, δ∗)
}
=E
{−1
piY
ACXCY
pipiXpiY
(Y − h1(X,Z,η))
}
= 0,
because of the way η and δ are estimated. Therefore, the influence function reduces to φ1(X,Z;P1,η∗, δ∗).
Similar reasonings lead to the estimator
µˆ0 = n
′−1
n′∑
i=1
1−Ai
1− pˆi
(
CYi C
X
i
pˆiY pˆiX
(Yi − Yˆ0i) + C
X
i
pˆiX
(Yˆ0i − Yˆ ′0i) + Yˆ ′0i
)
,
with influence function
φ0(X,Z;P0, ζ,ν) =
1−A
1− pi
[
CY CX
piY piX
{Y − h0(X,Z, ζ)}+ C
X
piX
{h0(X,Z, ζ)− f0(Z,ν)}
+f0(Z,ν)− P0
]
,
where E(Y |A = 0, X,Z) = h0(Z, X; ζ0) and E(Y ∗|A = 1,Z) = f0(Z;ν0). The asymptotic
variance of the estimator µˆ1 − µˆ0, denoted by s2, can then be straightforwardly estimated as one
over n′ times the sample variance of the values
φ1(X,Zi; µˆ1, ηˆ, δˆ)− φ0(X,Zi; µˆ0, ζˆ, νˆ).
Note that further efficiency can sometimes be gained by estimating the probabilities pi, piX and piY
conditional on the covariates. We can then use a weighted regression, based on these weights, to
impute the primary endpoint values in cohort 2 and 3.
Appendix B: Independent Increments Property
Define St as
A
pi
{
CY CX
piY piX
Y +
CX
piX
(
1− C
Y
piY
)
h1(X,Z,η0) +
(
1− C
X
piX
)
f1(Z, δ0)− µ1
}
− 1−A
1− pi
{
CY CX
piY piX
Y +
CX
piX
(
1− C
Y
i
piY
)
h0(X,Z, ζ0) +
(
1− C
X
piX
)
f0(Z,ν0)− µ0
}
,
and St,i as
Ai
pˆi
{
CYi C
X
i
pˆiYi pˆi
X
Y +
CXi
pˆiX
(
1− C
Y
i
pˆiY
)
h1(Xi,Zi, ηˆ) +
(
1− C
X
i
pˆiX
)
f1(Zi, δˆ)− µ1
}
− 1−Ai
1− pˆi
{
CYi C
X
i
pˆiY pˆiX
Y +
CXi
pˆiX
(
1− C
Y
i
pˆiY
)
h0(Xi,Zi, ζˆ) +
(
1− C
X
i
pˆiX
)
f0(Zi, νˆ)− µ0
}
,
where CYi and CXi are evaluated at interim time t. Then
√
n′ {(µˆ1 − µˆ0)− (µ1 − µ0)} = n′−1/2
n′∑
i=1
St,i.
Therefore, µˆ1− µˆ0 is an asymptotically linear estimator of µ1−µ0 whose influence function is given
by φi = St,i for the i-th subject. Suppose that we are interested in testing H0 : µ1−µ0 = µ01−µ00,
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then µj in the previous expression is replaced by µ0j (j ∈ {0, 1}):
n′−1/2
n′∑
i=1
St,i =
√
n′ {(µˆ1 − µˆ0)− (µ1 − µ0)}
=
√
n′SE(µˆ1 − µˆ0) {(µˆ1 − µˆ0)− (µ1 − µ0)} /SE(µˆ1 − µˆ0)
=
√
n′SE(µˆ1 − µˆ0)Zt
= Iˆ−1/2t Zt,
with SE(µˆ1 − µˆ0) the estimated standard error and Iˆt the observed information which equals
1/(SE(µˆ1 − µˆ0)2n′). Since It/Iˆt = SE(µˆ1 − µˆ0)2n′/σ2, with σ2 = Var(St) and It the expected
information, converges in probability to 1, we obtain that Zt = n′
−1/2∑n′
i=1 I1/2t St,i + op(1).
Moreover, note that Iˆ1/2t Zt is equal to n′−1/2
∑n′
i=1 ItSt,i + op(1).
Since the test statistic at the end of the study,
Z1 =
Pˆ1 − Pˆ0√
Pˆ1(1−Pˆ1)
n1
+ Pˆ0(1−Pˆ0)n0
where Pˆ1 =
∑n
i=1AiYi/
∑n
i=1Ai and Pˆ0 =
∑n
i=1(1−Ai)Yi/
∑n
i=1(1−Ai), is a special case of the
interim test statistic (with CX = CY = 1 for all patients and n′ = n), similar results hold for Z1.
Now consider a second interim analysis at time s and define Ss in a similar way as St but with
CX and CY evaluated at time s. To prove the independent increments assumption, it is sufficient
to establish that E[StIt(SsIs−StIt)] = 0, with t and s two arbitrary timepoints where 0 < t < s.
To do this, note that
E [S1(S1 − St)] =E
[
A
pi2
(Y − µ1)
{
(Y − µ1)− C
Y CX
piY piX
Y − C
X
piX
(
1− C
Y
piY
)
h1(X,Z,η
∗)
−
(
1− C
X
piX
)
f1(Z, δ
∗) + µ1
}]
− E
[
1−A
(1− pi)2 (Y − µ0)
{
(Y − µ0)− C
Y CX
piY piX
Y − C
X
piX
(
1− C
Y
piY
)
h0(X,Z, ζ
∗)
−
(
1− C
X
piX
)
f0(Z,ν
∗) + µ0
}]
=pi−1E
[
Y
{
Y − C
Y CX
piY piX
Y − C
X
piX
(
1− C
Y
piY
)
h1(X,Z,η
∗)
−
(
1− C
X
piX
)
f1(Z, δ
∗)
}∣∣∣∣A = 1]
− (1− pi)−1E
[
Y
{
Y − C
Y CX
piY piX
Y − C
X
piX
(
1− C
Y
piY
)
h0(X,Z, ζ
∗)
−
(
1− C
X
piX
)
f0(Z,ν
∗)
}∣∣∣∣A = 0]
=pi−1E
[
Y 2 − C
Y CX
piY piX
Y 2 − C
X
piX
(
1− C
Y
piY
)
h1(X,Z,η
∗)Y
−
(
1− C
X
piX
)
f1(Z, δ
∗)Y
∣∣∣∣A = 1]
− (1− pi)−1E
[
Y 2 − C
Y CX
piY piX
Y 2 − C
X
piX
(
1− C
Y
i
piY
)
h0(X,Z, ζ
∗)Y
−
(
1− C
X
piX
)
f0(Z,ν
∗)Y
∣∣∣∣A = 0]
=pi−1E
[
Y 2 − C
Y CX
piY piX
Y 2
∣∣∣∣A = 1]− (1− pi)−1E [Y 2 − CY CXpiY piX Y 2
∣∣∣∣A = 0]
=0.
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In a similar way, it can be shown that E [Ss(Ss − St)] = 0. Consequently, E [SsSt] = E
[
S2s
]
. With
this in mind,
E[StIt(SsIs − StIt)] = E[St/E[S2t ](Ss/E[S2s ]− St/E[S2t ])]
= E[StSs]/(E[S
2
t ]E[S
2
s ])− E[S2t ]/E[S2t ]2
= E[S2s ]/(E[S
2
t ]E[S
2
s ])− 1/E[S2t ]
= 0,
since It = 1/E
[
S2t
]
and Is = 1/E
[
S2s
]
. Because the basic Brownian motion joint distribution
structure is satisfied, the proposed test statistics can be imbedded in the conditional power method.
For the sake of completeness, we show in a similar way that the B-value Bt = Zt
√
t at informa-
tion time t is independent of the increment B1 −Bt = Z1 −Zt
√
t. To establish this, it is sufficient
to prove that Cov[StI1/2t
√It/I1, S1I1/21 − StI1/2t √It/I1] = 0, since t = ItI1 .
Cov[StI1/2t
√
It/I1, S1I1/21 − StI1/2t
√
It/I1] = E
[
StIt√I1
(
S1I1/21 −
StIt√I1
)]
= E [StS1] It − E
[
S2t
] I2t /I1
= E
[
S21
] It − E [S2t ] I2t /I1,
since It = 1/E
[
S2t
]
and I1 = 1/E
[
S21
]
, this yields
Cov[StI1/2t
√
It/I1, S1I1/21 − StI1/2t
√
It/I1] = E
[
S21
] It − E [S2t ] I2t /I1
= E
[
S21
]
/E
[
S2t
]− E [S2t ]E [S21] /E [S2t ]2
= E
[
S21
]
/E
[
S2t
]− E [S21] /E [S2t ]
= 0.
Because the basic Brownian motion joint distribution structure is satisfied, the proposed test statis-
tics can be imbedded in the conditional power method.
Appendix C: Sample Size Reassessment
This section focuses on the sample size reassessment based on conditional power arguments.
Appendix C.1: Independent Test Statistics
Since Zt
√
t |= (Z1−Zt
√
t), it is intuitively clear that the second stage test statistic should be based
on the independent increment Z1 − Zt
√
t. Moreover, this independence leads to the fact that
V ar(Z1 − Zt
√
t) = 1 − t since V ar(Z1) = V ar(Z1 − Zt
√
t) + V ar(Zt
√
t). We therefore suggest
the normalized statistic (Z1 −
√
tZt)/
√
1− t. It then follows directly from Appendix B that this
second stage test statistic is asymptotically independent of the first stage test statistic Zt, since:
Cov[Zt, (Z1 −
√
tZt)/
√
1− t] = Cov[√tZt, Z1 −
√
tZt]/(
√
1− t√t) = 0.
Appendix C.2: Theoretical Derivation of the Sample Size Reassessment Formula
Define θ = ∆
√
n/σ, with ∆ the treatment effect P1 − P0 used for powering the study and σ2
the common variance in both treatment arms. Introduce the artifical sample size at the interim
analysis as nB = t · n, let n2 correspond to the second-stage sample size and denote the adjusted
total sample size as n˜. Writing the assumption on the second stage data in terms of the second
stage sample size, the conditional power equations under the design effect can be rewritten as
CPt(θ) = 1− Φ
(
z1−α − Z(1)
√
w√
1− w − θ
√
n2
n
)
= 1− Φ
(
z1−α − Z(1)
√
w√
1− w −
θ√
n
√
n2
)
,
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where the weights w and 1 − w (0 ≤ w ≤ 1) are the pre-specified weights corresponding with the
first and second stage test statistic of the combination test. Since θ/
√
n = ∆/σ, n2 is the only
part of the equation that is not fixed at the time of the interim analysis. The target conditional
power, 1−β, can therefore be achieved by the choice of the second stage sample size n2 = n˜−nB ;
choosing n˜ such that the conditional power equals 1− β, gives
1− β = 1− Φ
(
z1−α − Z(1)
√
w√
1− w −
θ√
n
√
n˜− nB
)
⇐⇒ Φ−1(β) = z1−α − Z
(1)
√
w√
1− w −
θ√
n
√
n˜− nB
⇐⇒
√
n˜− nB =
z1−α−Z(1)√w√
1−w − Φ−1(β)
θ/
√
n
⇐⇒ n˜− nB = max
0,
 z1−α−Z(1)√w√1−w − Φ−1(β)
θ/
√
n

2
.
If n˜ ≤ n′, with n′ the number of recruited patients at the interim analysis, then no extra subjects
are recruited. Note that a second test statistic is still being calculated after the primary endpoint
is available for all n′ recruited patients. In practice, the sample size reassessment is often done
assuming the observed effect for the primary endpoint data in the remainder of the study. Similar
reasonings lead to
1− β = 1− Φ
(
z1−α − Z(1)
√
w√
1− w −
Z(1)/
√
t√
n
√
n˜− nB
)
⇐⇒ Φ−1(β) = z1−α − Z
(1)
√
w√
1− w −
Z(1)/
√
t√
n
√
n˜− nB
⇐⇒
√
n˜− nB =
z1−α−Z(1)√w√
1−w − Φ−1(β)
(Z(1)/
√
t)/
√
n
⇐⇒ n˜− nB = max
0,
 z1−α−Z(1)√w√1−w − Φ−1(β)
(Z(1)/
√
t)/
√
n

2
.
Appendix D: Theoretical Derivation of the Blinded Information Fraction
The blinded estimate of the variance of the estimator at the end of the study equals
V ar
[
A
pi
Y − 1−A
1− pi Y −
(
A
pi
µ− 1−A
1− pi µ
)]
= V ar
[(
A
pi
− 1−A
1− pi
)
(Y − µ)
]
= V ar
[
A− pi
(1− pi)pi (Y − µ)
]
= ((1− pi)pi)−1E [(Y − µ)2] ,
with µ the probability of success over the two treatment arms. However, during monitoring of the
trial, the primary endpoint is not observed for all patients. Nevertheless, we can calculate (Yi− µˆ)2
for each patient i for whom Yi is observed (CYi = 1) with µˆ =
∑n
i=1 C
Y
i Yi/
∑n
i=1 C
Y
i . Under the
assumption that Yi |= CYi , the variance is estimated as 1/(n(1 − pi)pi) times the sample mean of
(Y − µˆ)2 over the patients with observed Y data.
The variance of the blinded estimator obtained during monitoring of the trial on the other hand
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equals
V ar
[
ACXCY
pipiXpiY
(
Y − E(Y |CY = 1, Z,X))+ ACX
pipiX
(
E(Y |CY = 1, Z,X)− E(Y |CX = 1, Z))
+
A
pi
E(Y |CX = 1, Z)− (1−A)C
XCY
(1− pi)piXpiY
(
Y − E(Y |CY = 1, Z,X))
− (1−A)C
X
(1− pi)piX
(
E(Y |CY = 1, Z,X)− E(Y |CX = 1, Z))− 1−A
1− pi E(Y |C
X = 1, Z)
−A
pi
µ+
1−A
1− pi µ
]
=V ar
[
CXCY
piXpiY
{A/pi − (1−A)/(1− pi)} (Y − E(Y |CY = 1, Z,X))
+
CX
piX
{A/pi − (1−A)/(1− pi)} (E(Y |CY = 1, Z,X)− E(Y |CX = 1, Z))
+ {A/pi − (1−A)/(1− pi)}E(Y |CX = 1, Z)− {A/pi − (1−A)/(1− pi)}µ
]
=((1− pi)pi)−1E
[(
CXCY
piXpiY
(
Y − E(Y |CY = 1, Z,X))
+
CX
piX
(
E(Y |CY = 1, Z,X)− E(Y |CX = 1, Z))+ E(Y |CX = 1, Z)− µ)2] .
Thus, the variance is estimated as 1/(n′(1− pi)pi) times the sample mean of the values(
CXi C
Y
i
piXpiY
(
Yi − E(Yi|CYi = 1, Zi, Xi)
)
+
CXi
piX
(
E(Yi|CYi = 1, Zi, Xi)− E(Yi|CXi = 1, Zi)
)
+E(Yi|CXi = 1, Zi)− µˆ
)2
over all n′ recruited patients (CZi = 1).
Appendix E: R-squared
We define the total R-squared, which quantifies the proportion of variation in Y explained by X
and Z, as
R2 =
ˆV ar[βˆ0 + βˆ1X + βˆ2Z]
ˆV ar[βˆ0 + βˆ1X + βˆ2Z] + pi2/4
,
with βˆ0, βˆ1 and βˆ2 the estimated parameters in a logistic regression model for Y given X and
Z, E(Y |X,Z) = logit−1(β0 + β1X + β2Z) and ˆV ar(·) the empirical variance. The proportion of
variation explained by X cannot be directly derived from one logistic regression since the value
of X depends on Z. We therefore denote the estimated prediction Pˆ (Xi = 1|Zi) from a logistic
regression model with regressors Zi as Qˆ(Zi). We then define the proportion of variation in Y
explained by X as
R2X =
βˆ21V ar[X − Qˆ(Z)]
ˆV ar[βˆ0 + βˆ1X + βˆ2Z] + pi2/4
.
Note that we cancel out the variation in Y explained by X via Z by incorporating V ar[X− Qˆ(Z)]
to obtain the variation uniquely explained by X. We define the proportion of variation explained
by Z is given by
R2Z =
V ar[βˆ1Qˆ(Z) + βˆ2Z]
ˆV ar[βˆ0 + βˆ1X + βˆ2Z] + pi2/4
,
which guarantees that R2 = R2X +R
2
Z .
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Appendix F: Tables
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Table 7: Operating characteristics of a trial with sample size re-assessment based on conditional
power as futility stopping rule at the time 50% of the total information is obtained. Results are
based on 10, 000 (10, 0000 for null hypothis) Monte Carlo simulations.
Treatment Effect
0 0.09 0.13 0.16
Power One Stage Trial 2.62% 58.67% 90.52% 98.73%
Proposal Average # Days 970 951 942 934
FS 59.9% 9.5% 1.9% 0.3%
Power Loss 0.08% 0.78% 0.56% 0.16%
Power No SSR 2.54% 57.89% 89.96% 98.57%
Q0 No SSR 466 470 466 480
Q1 No SSR 507 638 638 638
Q2 No SSR 514 638 638 638
Q3 No SSR 638 638 638 638
Q4 No SSR 638 638 638 638
ASS No SSR 560(64) 625(41) 635(20) 638(9)
Power SSR 2.44% 73.21% 94.21% 98.62%
Q0 SSR 466 463 448 447
Q1 SSR 507 503 492 487
Q2 SSR 514 817 507 495
Q3 SSR 1276 1276 903 513
Q4 SSR 1276 1276 1202 1196
ASS SSR 782(358) 880(349) 711(308) 589(227)
% Rejected with SSR, not without 3.0% 60.1% 80.8% 89.1%
% Not rejected with SSR, rejected without 48.8% 7.4% 2.6% 0.9%
Standard CP Average # Days 1032 1032 1032 1032
FS 60.1% 9.7% 2.1% 0.3%
Power Loss 0.09% 0.93% 0.67% 0.18%
Power No SSR 2.53% 57.74% 89.85% 98.55%
Q0 No SSR 536 540 540 539
Q1 No SSR 540 638 638 638
Q2 No SSR 543 638 638 638
Q3 No SSR 638 638 638 638
Q4 No SSR 638 638 638 638
ASS No SSR 579(48) 629(29) 636(14) 638(5)
Power SSR 2.52% 74.50% 95.05% 99.00%
Q0 SSR 536 536 536 535
Q1 SSR 540 540 540 539
Q2 SSR 543 827 543 542
Q3 SSR 1276 1276 914 546
Q4 SSR 1276 1276 1205 1199
ASS SSR 802(345) 898(334) 735(291) 627(208)
% Rejected with SSR, not without 3.2% 61.3% 80.5% 82.5%
% Not rejected with SSR, rejected without 46.9% 5.5% 1.4% 0.5%
Note: Power One Stage Trial, a reference power of one stage trial where no interim analyses or adaptations are
conducted; Average # Days, average number of days elapsed since beginning of the study; FS, probability to stop for
futility using O’Brien Fleming boundaries; Power Loss, loss of power when conducting an interim analysis compared
to the design power; Power SSR/No SSR, Power when there is/is no sample size re-assessment; Qi SSR/No SSR, ith
quantile of the sample size when there is/is no sample size re-assessment; ASS SSR/No SSR, average sample size over
both stages and its standard deviation (in brackets); % Rejected with SSR, not without, proportion of trials that were
not stopped and not rejected without SSR that are rejected with SSR; % Not rejected with SSR, rejected without,
proportion of trials that were not stopped and rejected without SSR that are not rejected with SSR.
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Figure 1: True Futility: Comparison of the information fraction and the probability to stop for
futility between the standard conditional power approach and the conditional power using the pro-
posed interim estimator for different scenarios under true futility. True Superiority: Comparison of
the information fraction and the loss of power compared to the design power between the standard
conditional power approach and the conditional power using the proposed interim estimator for
different scenarios under superiority. The interim analysis is conducted at a fixed point in time.
(a) True Futility
(b) Superiority
Note: t and tst, average information fraction using respectively the proposed and usual test statistic in the condi-
tional power approach; R20, "R squared" is the proportion of the variance in the dependent variable in the control
arm that is predictable from Z = Z1; Power Loss, loss of power when conducting an interim analysis compared to
the design power.
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Figure 2: Comparison of percentages of patients recruited at the time of the interim analysis be-
tween the standard conditional power and the porposed conditional power for different information
fractions. Setting: Futility c = 2.
Figure 3: Visualisation of the model misspecfication for outcome working models 2 and 3: expected
Y values under the correctly specified model and outcome working models 2 and 3 are plotted
against Z1.
(a) Outcome working model 2 (b) Outcome working model 3
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